ArticleThe Journal of clinical investigation1994
Cyclosporin A inhibits CD40 ligand expression in T lymphocytes.
Article in The Journal of clinical investigation, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 140 citations in OpenAlex.
- Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo.Clinical and experimental immunology · 2002Trial
- Hyperimmunoglobulin syndromes: A review of HIGM, HIES, and HIDS.Journal of translational autoimmunity · 2025Review
- Monoclonal antibody-mediated immunosuppression enables long-term survival of transplanted human neural stem cells in mouse brain.Clinical and translational medicine · 2022Article
- Clinical and molecular features of X-linked hyper IgM syndrome - An experience from North India.Clinical immunology (Orlando, Fla.) · 2018Article
- CD40LG duplication-associated autoimmune disease is silenced by nonrandom X-chromosome inactivation.The Journal of allergy and clinical immunology · 2018Article
- Application of Operational Tolerance Signatures Are Limited by Variability and Type of Immunosuppression in Renal Transplant Recipients: A Cross-Sectional Study.Transplantation direct · 2017Article
- Immunosuppressive compounds exhibit particular effects on functional properties of human anti-Aspergillus Th1 cells.Infection and immunity · 2014Article
- The hyper IgM syndromes.Clinical reviews in allergy & immunology · 2014Review
- Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by Δ(9)-tetrahydrocannabinol in human CD4(+) T cells.Toxicology and applied pharmacology · 2013Article
- Differential modulation by delta9-tetrahydrocannabinol (∆9)-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cells.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2012Article
- Cyclosporine-resistant, Rab27a-independent mobilization of intracellular preformed CD40 ligand mediates antigen-specific T cell help in vitro.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Article
- Dermatomyositis, complicated with pneumomediastinum, successfully treated with cyclosporine A: a case report and review of literature.Rheumatology international · 2009Review
- Functional analysis of a tripartite stability element within the CD40 ligand 3' untranslated region.Immunology · 2008Article
- Article
- Targeting CD40L: a promising therapeutic approach.Clinical and diagnostic laboratory immunology · 2004Review
- Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression.Molecular and cellular biology · 2003Article
- CD154 transcriptional regulation in primary human CD4 T cells.Immunologic research · 2003Review
- New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs.Annals of surgery · 2002Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
The ligand for CD40 is expressed on activated T lymphocytes and delivers contact-dependent activation signals to B lymphocytes. The mechanisms regulating CD40 ligand gene expression are largely unknown. Optimal expression of CD40 ligand required activation of protein kinase C and a rise in intracellular calcium concentration. CD40 ligand expression was inhibited by pretreatment of T cells with cyclosporin A. Cyclosporin A analogues inhibited CD40 ligand expression with a potency mirroring the ability of each compound to inhibit calcineurin activity, indicating that calcineurin plays a key role in CD40 ligand gene expression. Cyclosporin A inhibited IL-4-driven CD40 ligand-dependent IgE isotype switching in PBMC but did not inhibit IgE synthesis induced by CD40 mAb plus IL-4. PBMC derived from transplant patients receiving cyclosporin A failed to express CD40 ligand upon stimulation. These results suggest that patients receiving cyclosporin A may be deficient in CD40 ligand-dependent T cell help.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.